Business Context and Reporting Period
This Form 8-K is a current report filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on August 4, 2009. The registrant is a Delaware corporation headquartered in San Diego, California. The filing reports a material event under Item 8.01 regarding the company's drug development progress.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a corporate event and references a prior equity financing from June 2009 without disclosing specific financial figures.
Material Changes
- Regulatory Submission Plan: The company announced its intention to submit a New Drug Application (NDA) for ANX-530 (vinorelbine emulsion) around the end of 2009.
- Manufacturing Milestone: ADVENTRX successfully completed the final manufacturing activities required for the NDA submission.
- Operational Restart: These manufacturing activities were re-started following an equity financing event in June 2009.
Outlook, Risks, and Management Commentary
Management commentary is limited to the press release incorporated by reference (Exhibit 99.1), which highlights the successful completion of manufacturing as a direct result of the June 2009 capital raise. The filing does not provide specific forward-looking guidance, risk factors, or contingencies beyond the stated timeline for the NDA submission.
Investor Verification Checklist
- Verify the exact date of the NDA submission for ANX-530 against the "end of 2009" target.
- Review the June 2009 equity financing details to understand the capital structure supporting the manufacturing restart.
- Confirm the regulatory status of ANX-530 with the FDA to validate the NDA submission timeline.
- Note the discrepancy between the requested company name (Savara Inc.) and the actual registrant (ADVENTRX Pharmaceuticals, Inc.).